Wedbush analyst Matt Bryson maintains Micron Technology (NASDAQ:MU) with a Outperform and lowers the price target from $120 to $85.
Initial Clinical Data Reported From Immutep’s Efti Combined With Radiotherapy And Checkpoint Inhibitor From Phase II Trial In Soft Tissue Sarcoma
Novel triple combination of efti with radiotherapy and anti-PD-1 therapy is well tolerated and has led to encouraging initial efficacy data in EFTISARC-NEO Phase II trialFour of six patients treated have very good,
